Claims
- 1. A compound of the formula: or a pharmaceutically acceptable salt thereof.
- 2. A compound of the formula:
- 3. A composition comprising a compound of the formula: or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, diluent or excipient.
- 4. A method of potentiating glutamate receptor function in a patient, which comprises administering to said patient an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof.
- 5. A method of treating depression in a patient comprising administering to said patient an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof.
- 6. A method of treating schizophrenia in a patient comprising administering to said patient an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof.
- 7. A method of treating cognitive disorders in a patient comprising administering to said patient an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof.
- 8. A process for the preparation of a compound of formula Ia: comprising, nitrating a sulfonamide (5): to provide a p-nitro derivative (6): hydrogenating the p-nitro derivative (6) to provide a p-amino derivative (7): treating the p-amino derivative (7) with a suitable acid, then treating with a suitable base, and then treating with 3,5difluorobenzoyl chloride.
- 9. An article of manufacture comprising packaging material and a compound of formula: or a pharmaceutically acceptable salt thereof contained within said packaging material, wherein said packaging material comprises a label which indicates that said compound can be used for treating at least one of the following; Alzheimer's disease, schizophrenia, cognitive deficits associated with schizophrenia, depression, and cognitive disorders.
- 10. An article of manufacture according to claiam 9 wherein said label indicates that said compound can be used for treating Alzheimer's disease.
- 11. An article of manufacture according to claim 9 wherein said label indicates that said compound can be used for treating schizophrenia.
- 12. An article of manufacture according to claim 9 wherein said label indicates that said compound can be used for treating depression.
- 13. An article of manufacture according to claim 9 wherein said label indicates that said compound can be used for treating cognitive deficits associated with schizophrenia.
- 14. A method of treating Parkinson's disease in a patient comprising administering to said patient an effective amount of a compound of the formula:
- 15. A method of treating Alzheimer's disease in a patient comprising administering to said patient an effective amount of a compound of the formula:
Parent Case Info
This is the national phase application, under 35 USC 371, for PCT/US01/11746 filed May 4, 2001, which claims the priority of U.S. Provisional Application No. 60/205,822 filed May 19, 2000.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US01/11746 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO01/90056 |
11/29/2001 |
WO |
A |
Foreign Referenced Citations (6)
Number |
Date |
Country |
0 860 428 |
Aug 1998 |
EP |
WO 9833496 |
Feb 1997 |
WO |
WO 0006148 |
Jul 1998 |
WO |
WO 0006156 |
Jul 1998 |
WO |
WO 0006158 |
Jul 1998 |
WO |
WO 0006537 |
Jul 1998 |
WO |
Non-Patent Literature Citations (1)
Entry |
U.S. patent application Ser. No. 60/329,056, Bleakman et al., filed Oct. 12, 2001. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/205822 |
May 2000 |
US |